Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (2025)
10 slides from Bayer's technical presentation, 2025
Slide 1: Finerenone and Liver Fibrosis Assessed by FIB-4 Index in Heart Failure
Finerenone And Liver Fibrosis Assessed By Fibrosis-4 (FIB-4) Index In Patients With Heart Failure And Mildly Reduced Or Preserved Ejection Fraction - Results From The FINEARTS- HF Trial Mingming Yang, MD PhD | University of Glasgow, Glasgow, United Kingdom #AHA25
Slide 2: Disclosures
Disclosures Relevant financial relationships: Travel grant from Bayer Relevant nonfinancial relationships Nothing to disclose 2
Slide 3: Background: Liver fibrosis and HFmrEF/HFpEF
Background: Liver fibrosis and HFmrEF/HFpEF • Liver fibrosis is thought to be a potentially common comorbidity in heart failure (HF), driven by hepatic venous congestion and hypoperfusion, systemic inflammation, and metabolic disturbances. • The fibrosis-4 (FIB-4) index is an established non-invasiv
Slide 4: FINEARTS-HF Study Design
FINEARTS-HF Study Design Prospective, randomized, double-blind, placebo-controlled trial comparing finerenone to placebo in patients with heart failure and left ventricular ejection fraction (LVEF) ≥ 40% • Age ≥40 years • Structural Heart Disease • NYHA class II-IV • (LVH or LA Enlargement) • LVEF ≥
Slide 5: Fibrosis-4 (FIB-4) index in FINEARTS-HF
Fibrosis-4 (FIB-4) index in FINEARTS-HF N = 5476 (91.1%) had FIB-4 index calculable at baseline ….p
Slide 6: Baseline characteristics according to baseline FIB-4 index
Baseline characteristics according to baseline FIB-4 index Low likelihood Intermediate likelihood High likelihood P for trend <1.30 (n=3166) 1.30-2.67 (n=1433) >2.67 (n=877) Age (years), mean 70.4 71.8 77.7 <0.001 Male sex, % 50.7 60.5 59.5 <0.001 SBP (mmHg), mean 129.9 129.1 128.0 0.001 BMI (kg/m2)
Slide 7: Baseline characteristics according to baseline FIB-4 index
Baseline characteristics according to baseline FIB-4 index Low likelihood Intermediate likelihood High likelihood P for trend <1.30 (n=3166) 1.30-2.67 (n=1433) >2.67 (n=877) ALT (U/L), mean 19.8 21.0 22.5 0.040 AST (U/L), mean 19.6 24.5 31.9 <0.001 ALT/AST ratio, median 1.1 1.3 1.5 <0.001 Hepatic st
Slide 8: Cumulative incidence of clinical outcomes according to baseline FIB-4 index
Cumulative incidence of clinical outcomes according to baseline FIB-4 index Total HF events and CV death All-cause death
Slide 9: Effect of finerenone versus placebo on primary endpoint by FIB-4 index
Effect of finerenone versus placebo on the primary endpoint according to FIB-4 index (and on FIB-4 index) Total heart failure events Percent patients with improvement and CV death or deterioration in FIB-4 category* *percent of patients with improvement/ deterioration between 9 baseline and 12 month
Slide 10: Conclusions: Finerenone and FIB-4 index in patients with HFmrEF/HFpEF
Conclusions: Finerenone and FIB-4 index in patients with HFmrEF/HFpEF • In FINEARTS-HF, about 1 in 6 patients had a high FIB-4 score indicating a high likelihood of liver fibrosis (although this remains to be confirmed in heart failure). • FIB-4 score independently predicted the risk of clinical out